Immunohistochemistry analysis demonstrated that XCL1 expression on tumor cells was positively correlated with the number of tumor-infiltrating CD8-positive T cells and PD-L1 expression on tumor cells, which were predictive biomarker candidates in an immune checkpoint therapy in various types of malignancies. This evidence concerns the gene CD274 and neoplasm.